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Review
A review of the published literature on Rh alloimmunization 
reveals that its incidence varies with the volume of infused D+ red 
blood cells (RBCs), the probable Rh genotype of the RBCs, and 
the immune competency of the D– recipient. Among the reports 
of Rh alloimmunization in different clinical circumstances, 
we identified five studies in which a combined total of 62 D– 
recipients of hematopoietic stem cell or solid-organ transplants 
were transfused with D+ RBCs and none (0%) formed anti-D. 
The observation that immunosuppressive protocols developed to 
prevent rejection of tissue and organ transplants also prevented 
alloimmunization to the D blood group antigen raises the 
possibility of practical applications in blood transfusion practice. 
Immunohematology 2013;29:110–14.
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The incidence of Rh alloimmunization, i.e., the formation 
of anti-D, when D+ red blood cells (RBCs) are transfused to D– 
recipients, varies with the volume of infused D+ RBCs, their 
Rh genotype, and the immune competency of the recipient.1 
As an initial step in drafting a protocol to study transfusion-
related Rh alloimmunization in patients, we conducted a 
review of published literature on Rh alloimmunization. The 
following report describes the result of our review and suggests 
how immunosuppressive protocols may benefit selected 
transfusion recipients who are at risk of alloimmunization to 
blood group antigens.
Materials and Methods
We conducted PubMed and OVID Medline searches of 
journal articles associated with the following key words: Rh 
alloimmunization, anti-D, and Rh-positive RBCs. The literature 
search included articles published during the years 1956 to 
2013. We limited the search to journal articles published in the 
English language. We searched pertinent sections of standard 
textbooks in transfusion medicine for citations to additional 
original journal articles.1–4 We conducted a parallel search 
for journal articles on D-mismatched platelet transfusions 
and hematopoietic stem cell or solid-organ transplants, 
considering Rh alloimmunization in these patients to be a 
consequence of contaminating donor-derived D+ RBCs in 
the component. We summarized the results of our review in 
a figure that illustrates the incidence of Rh alloimmunization 
for various categories of immune-competent versus immune-
compromised D– patients who had received transfusions of 
D+ RBCs (Figure 1).
Results
Small Doses of Red Blood Cells Infused in Immune-
Competent Recipients
Several studies describe experimental Rh alloimmuniza-
tion in immune-competent D– persons with D+ RBCs for 
purposes of basic research, as control subjects in studies of 
Rh immunoprophylaxis, or for immunizing volunteer donors 
Fig. 1 Incidence of Rh alloimmunization in D– persons by recipients’ 
immune status and disease categories. The numbers in the graph 
refer to articles cited in References. *After a second (booster) 
infusion; †after one infusion.
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for the collection of plasma containing anti-D for manufacture 
of Rh immune globulin (RhIG).2–9,29 The results of these 
studies indicate a general trend for an increasing incidence 
of Rh alloimmunization in relation to the volume of infused 
D+ RBCs and the Rh genotype (Table 1). Mollison et al.1,5 
reviewed their studies, as well as those of others who infused 
small doses of D+ RBCs in immune-competent recipients. 
They concluded that approximately 20 percent of D– subjects 
infused with DCe/ce RBCs formed anti-D compared with 35 
percent who received DCe/DcE or DcE/DcE RBCs. After a 
second infusion, the incidence of Rh alloimmunization nearly 
doubled (35% and 63%, respectively). At 1 year, 30 percent 
of subjects receiving DCe/ce RBCs formed anti-D compared 
with 84 percent receiving DcE/ce.1 Collectively, these studies 
demonstrate that for small-volume infusions in D– immune-
competent recipients, DcE/DcE RBCs are more immunogenic 
than DCe/Ce or DCe/DCe RBCs. This observation is supported 
by studies demonstrating a lower mean concentration of D on 
DCe/ce RBCs (240 pmol/mL) compared with DcE/DcE (473 
pmol/mL).30
Whole Units of Red Blood Cells in Immune-
Competent Recipients
When larger volumes of D+ RBCs (500-mL units) were 
transfused to immune-competent recipients, the incidence 
of Rh alloimmunization was significantly higher, obscuring 
the effect of the Rh genotype on the incidence of Rh 
alloimmunization.11,30
Immune-Competent D– Volunteers
In a study of Rh prophylaxis, Pollack et al.10 reported an 
incidence of 81.8 percent (18 of 22) Rh alloimmunization 
5 months after transfusion of one 500-mL unit of DCe/ce 
RBCs in D– volunteers. Urbaniak and Robertson11 reported 
their experience in a program infusing D+ RBCs to D– men for 
manufacture of RhIG. They infused 200 mL of frozen-thawed 
RBCs (DCe/DCe, DcE/DcE, or DCe/DcE) followed by serial 
boosters of 5 mL of RBCs from the same donor. The incidence 
of Rh alloimmunization was 87 percent (24 of 28) after the 
initial 200-mL infusion and 93 percent (26 of 28) after the 
booster infusions. The Rh genotype of the immunizing RBCs 
did not appear to be an important factor in determining the 
incidence of Rh alloimmunization. DCe/DCe RBCs were as 
effective as DcE/DcE. All D– recipients of DCe/DcE RBCs 
formed anti-D.
D– Patients Not Receiving Immunosuppressive 
Therapy
Yazer and Triulzi13 reported a 22 percent (22 of 98) 
incidence of Rh alloimmunization in D– nononcology patients 
who were transfused with D+ RBCs and followed for a mean 
of 182 days. Frohn et al.14 reported Rh alloimmunization in 
30.4 percent (16 of 78) of D– recipients of D+ RBCs. The 
patients in this study had various medical and surgical 
diagnoses, but hematologic disorders requiring treatment 
with immunosuppressive regimens were excluded. Gonzalez-
Porras et al.12 reported a 21.4 percent (34 of 159) incidence of 
Rh alloimmunization in a general hospital population after a 
prospective median follow-up of 41 days.
Immune-Compromised Patients
Expectedly, the incidence of alloimmunization to blood 
group antigens was decreased when D+ RBCs were transfused 
to D– patients whose immune function is compromised 
by disease or immunosuppressive therapy. Ting et al.31 
reported the formation of antibodies in 8.7 percent (13 of 150) 
transfusion recipients after bone marrow transplantation. They 
suggested that the blood group antibodies could be the result of 
transfusion of lymphocytes with the donor’s bone marrow, the 
ability of the grafted immune system to produce alloantibodies, 
or the viability of the residual host’s immune system despite 
chemotherapy and irradiation.31 After eliminating antibodies 
formed by three recipients whose transfused RBCs did not 
express the corresponding antigens, and excluding other 
antibodies that were transient and attributed to residual 
host lymphocytes, the incidence of alloimmunization was 
only 2 percent (3 of 150).31 Abou-Elella et al.32 also reported 
a relatively low incidence of alloimmunization to blood group 
antigens after bone marrow transplantation, namely, 2 percent 
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Table 1. Incidence of Rh alloimmunization in D– immune-




Incidence of Rh 
alloimmunization Reference










12 DCe/DcE RBCs/tested  
at 6 months
42% 7
1.0 mL/2 or 
3 doses
12 DcE/DcE RBCs/tested  
at 12 months
50% 8
0.5 mL 6 DcE/DcE RBCs/tested  
for anti-D at 210 days
83.3% 9
5.0 mL 6 DcE/DcE RBCs/tested  
for anti-D at 150 days
83.3% 9
RBCs = red blood cells.
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or 0.1 percent per unit of transfused RBCs to 193 bone marrow 
transplant recipients.
We identified five reports of Rh alloimmunization in D– 
transplantation patients who had been treated with immuno-
suppressive protocols and transfused with D+ RBCs.15–19 
Typically, the more intensive immunosuppressive protocols 
were for non–ABO-incompatible hematopoietic progenitor cell 
transplants, followed by non–ABO-incompatible solid-organ 
transplants, ABO-compatible hematopoietic cell transplants, 
and ABO-compatible solid-organ transplants, as follows:
Hematopoietic Stem Cell Transplants. Mijovic15 reported 
that none of nine (0%) D– recipients of nonmyeloablative 
hematopoietic stem cell transplants from D+ donors developed 
anti-D, although they had also received transfusions (7 to 
499 mL) of D+ RBCs. There were six unrelated bone marrow 
donors and three sibling peripheral blood progenitor cell 
donors. The nonmyeloablative conditioning regimens were 
fludarabine, alemtuzumab (Campath, Bayer Healthcare 
Pharmaceuticals, Montville, NJ), and busulfan (FBC or 
FB16C) or bis-chloroethylnitrosourea (BCNU), etoposide, 
alemtuzumab (Campath, Genzyme Corporation, Cambridge, 
MA), melphalan, and cytosine arabinoside  (BEAM-C). 
Cid et al.16 reported that none of 15 (0%) D– bone marrow 
transplant recipients developed anti-D, although all had 
received allogeneic hematopoietic stem cell transplants and 
transfusions of platelets from D+ donors. The patients had 
been treated with myeloablative (cyclophosphamide, plus 
total body irradiation of fludarabine) or nonmyeloablative 
(fludarabine and busulfan or melphalan) conditioning.
Solid-Organ Transplants. Ramsey et al.17 reported that 
none of 16 (0%) D– liver, heart, and heart-lung transplant 
recipients developed anti-D when tested 2.5 to 51 months 
after transfusions of D+ RBCs (3–153 units, median 10 units). 
The immunosuppressive regimen consisted of cyclosporine, 
corticosteroids, adjunctive rabbit antilymphocyte globulin, 
and in some cases OKT3 monoclonal antibody. Casanueva et 
al.18 reported no anti-D in 17 (0%) D– liver transplant patients 
receiving D– orthotopic liver transplants who were transfused 
with D+ units of red cells. The conditioning regimen was 
cyclosporine A, prednisone, azathioprine, and adjunctive rabbit 
antilymphocyte globulin or monoclonal OKT3 antibody. Yaun 
et al.19 also reported 0 percent (0 of 15) Rh alloimmunization in 
D– liver transplant recipients who received D– orthotopic liver 
transplants, but were transfused with D+ RBCs. In all of these 
reports, the investigators proposed that immunosuppression 
was the major contributing factor for the absence of anti-D in 
the D– recipients.15–19
In summary, all 62 D– recipients (100%) in these five 
reports of immunosuppression for hematopoietic stem cell 
or solid-organ transplants received transfusions of D+ RBCs 
without forming detectable anti-D.15–19
Immune-Compromised Patients With AIDS
Boctor et al.20 reported absence (0%) of Rh alloimmuniza-
tion in eight patients with AIDS who were transfused with D+ 
RBCs. This study underscores the importance of T cells to the 
humoral (B cell) immune response.
D-Mismatched Platelet Transfusions
Although D is not expressed on platelet membranes in 
persons who inherit RHD,33 the methods for preparing whole 
blood (WB)-derived (random donor) platelet concentrates 
result in sufficient volumes of contaminating RBCs to 
potentially cause Rh alloimmunization. The volume of 
RBCs in one unit of WB-derived platelet concentrates varies 
from trace to 0.5 mL.34 The volume of RBCs in one unit of 
apheresis platelets, which does not appear to be adequate 
to stimulate an immune response, is 0.0002 to 0.007 mL.34 
Goldfinger and McGinnis24 observed a 7.8 percent (8 of 102) 
incidence of Rh alloimmunization when D– oncology patients 
were transfused with platelet-rich plasma or pooled platelet 
concentrates from D+ donors. All but one of the recipients had 
received immunosuppressive treatment for malignant disease. 
Lichtiger et al.21 reported that none of 30 (0%) D– oncology 
patients formed anti-D after transfusions with platelets from 
D+ donors. Baldwin et al.25 reported an 18 percent (9 of 49) 
incidence of Rh alloimmunization in D– patients with leukemia 
and multiple myeloma, including two who received a bone 
marrow transplant and had received platelets or granulocyte 
transfusions from D+ donors. Cid et al.22 conducted a 
prospective study and reported that none of 22 (0%) D– adult 
patients with hematologic diseases who were transfused with 
platelets from D+ donors developed anti-D. The recipients 
had been treated with various immunosuppressive regimens, 
including autologous bone marrow transplantation. Molnar 
et al.23 observed no Rh alloimmunization in 42 (0%) D– 
pediatric oncology patients (7 hematopoietic cell transplant 
recipients and 35 chemotherapy only) who were transfused 
with leukocyte-reduced apheresis platelets from D+ donors. 
Asfour et al.28 reported a 4 percent (3 of 78) incidence of Rh 
alloimmunization when D– hematopoietic cell transplant 
recipients received a mix of WB-derived and apheresis platelets 
from D+ donors. Cid et al.27 reported Rh alloimmunization 
in 3.8 percent (12 of 315) D– patients who had received 
transfusions of platelet concentrates from D+ donors. In this 
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study, 4.8 percent of immunosuppressed and 1.9 percent 
of immune-competent recipients formed anti-D, but the 
difference in the incidence of Rh alloimmunization was not 
statistically significant. Similarly, Atoyebi et al.26 observed no 
Rh alloimmunization when 24 (0%) D– oncology patients were 
transfused with a mix of WB-derived and apheresis platelets, 
whereas 13.5 percent (8 of 59) patients with nonhematologic 
diseases developed anti-D after transfusion with similar 
platelet components from D+ donors.
Discussion
Two significant observations are apparent from this 
review. First, when small volumes of D+ RBCs (0.5–1.0 mL) 
are infused in D– immune-competent volunteers, there is 
a relatively low incidence of Rh alloimmunization. Given 
the incomplete and variable immune response to small 
doses of D+ RBCs, it is possible to distinguish the relatively 
greater immunogenicity of DcE/ce versus DCe/ce RBCs and 
of DcE/DcE versus DCe/DCe RBCs. The incidence of Rh 
alloimmunization increases generally with the volume of 
infused D+ RBCs, peaking at approximately 85 percent.1 
There is no known explanation for the failure of approximately 
15 percent of apparently immune-competent D– recipients, 
who are conventionally designated as nonresponders of D+ 
RBCs, to form anti-D.1
Second, and most importantly, the results of this review 
indicate that recently developed immunosuppressive protocols 
for hematopoietic cell or solid-organ transplantation are 
capable of preventing the primary humoral immune response 
when D+ RBCs are transfused to D– recipients. This effect 
has been observed for transfusions of D+ WB and for WB-
derived platelet concentrates from D+ donors to D– transplant 
recipients. The effect is not unexpected as the agents for 
transplant recipients are selected because of their capability of 
suppressing hosts’ immune responses to antigens expressed on 
donors’ organs and tissues. Newer nonmyeloablative protocols 
for bone marrow transplantation in sickle cell disease should 
offer not only improved clinical outcomes but also concomitant 
prevention of alloimmunization to D and other blood group 
antigens with less toxicity.35
Given the chronic shortage of D– RBCs in transfusion 
services worldwide, these observations have potential 
practical application for transfusion practice. The safe 
transfusion of D– transplant recipients with D+ RBCs 
without Rh alloimmunization raises the possibility that 
similar immunosuppressive protocols may allow transfusion 
of D+ RBCs in other categories of D– patients in times of 
critical shortage when, otherwise, they would be highly likely 
to become alloimmunized to D. Extending the implications 
of these findings to the subject of alloimmunization to other 
(non-D) blood group antigens, the possibility arises that a 
relatively short course of pretransfusion or posttransfusion 
immunosuppression could prevent the formation of other 
blood group alloantibodies in different patient populations, for 
example, sickle cell disease. If prevention of the primary humoral 
immune response to blood group antigens can be achieved 
with clinically tolerable doses of immunosuppressive agents—
without suppressing erythropoiesis in sickle cell patients—the 
potential applications are considerable. Recognizing that RhIG 
prevents Rh alloimmunization in postpartum women when 
administered as late as 72 hours after exposure to D+ RBCs, it 
is not unreasonable to encourage investigation of postexposure 
immunosuppression after D– persons have been transfused 
with D+ RBCs. It is conceivable that the observed side effect 
of suppression of Rh alloimmunization in D– transplant 
recipients will open opportunities for prophylactic protocols 
for future patients whose inherited blood groups place them 
at risk of complications, alloimmunization, and a lifelong 
requirement for uncommon and rare RBCs.
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